POY_1170x120_8-12-19

Upsher-Smith Laboratories

Upsher-Smith launches vigabatrin under brand name Vigadrone

Upsher-Smith launches vigabatrin under brand name Vigadrone

MAPLE GROVE, Minn. —  Upsher-Smith Laboratories  announced the launch of Vigadrone (vigabatrin) for Oral Solution, 500 mg, a fully substitutable, AA-rated generic version of Sabril (vigabatrin) powder for oral solution. The product was approved by the U.S. Food and Drug Administration (FDA) on June 21, 2018. The Vigabatrin powder market had U.S. sales of approximately $333 million for the 12 months

Upsher-Smith releases Doxazosin tablets

Upsher-Smith releases Doxazosin tablets

MAPLE GROVE, Minn. — Upsher-Smith Laboratories, LLC (Upsher-Smith) announced the launch of Doxazosin tablets, USP, 1 mg, 2 mg, 4 mg and 8 mg. The product was approved by the U.S. Food and Drug Administration (FDA) on April 17, 2018. Upsher-Smith’s Doxazosin tablets are an AB-rated generic version of the branded product, Cardura (doxazosin mesylate

Upsher-Smith parent sells stake in U.S. generics unit

Upsher-Smith parent sells stake in U.S. generics unit

MAPLE GROVE, Minn. — Upsher-Smith Laboratories LLC said its Japan-based parent, Sawai Pharmaceutical Co., has agreed to sell a 20% stake in its Sawai America Inc. subsidiary to Sumitomo Corp. of Americas (SCOA). Under the deal, SCOA — part of global conglomerate Sumitomo Corp. — is slated to buy the interest in Sawai America for $211

Upsher-Smith goes live with new Qudexy XR website

Upsher-Smith goes live with new Qudexy XR website

MAPLE GROVE, Minn. — Upsher-Smith Laboratories LLC has launched an enhanced website for its Qudexy XR anti-epileptic and migraine medication. Upsher-Smith said Monday that QudexyXR.com features the company’s Access Pathways Program aimed at reducing the barriers associated with prescribing Qudexy XR (topiramate). QudexyXR.com also offers health care providers tools necessary to help their patients “Start,

HDA honors drug companies with 2017 DIANA awards

HDA honors drug companies with 2017 DIANA awards

PHOENIX — The Healthcare Distribution Alliance (HDA) this week presented its annual Distribution Industry Awards for Notable Achievements in Healthcare (DIANA) to pharmaceutical manufacturers for supply chain innovation and collaboration. Given at the HDA 2017 Business and Leadership Conference in Phoenix, the DIANA awards honor HDA member manufacturers that develop innovative new products and promotions

Sawai wraps up acquisition of Upsher-Smith generics unit

Sawai wraps up acquisition of Upsher-Smith generics unit

TOKYO and MINNEAPOLIS — Sawai Pharmaceutical Co. Ltd. has closed its $1.05 billion acquisition of the Upsher-Smith Laboratories generic drug business. Sawai, which unveiled the deal with Upsher-Smith parent Acova Inc. in April, plans to retain Upsher’s headquarters in Minnesota and operation in Colorado. And as previously announced, Upsher-Smith will retain its current leadership, with

Upsher-Smith releases Anafranil generic

Upsher-Smith releases Anafranil generic

MAPLE GROVE, Minn — Upsher-Smith Laboratories Inc. has launched clomipramine hydrochloride capsules, an antidepressant, in the United States. Upsher-Smith said its clomipramine hydrochloride comes in dosages of 25 mg, 50 mg and 75 mg in 100-count bottles and is a generic version of Anafranil capsules from Mallinckrodt Pharmaceuticals. A tricyclic antidepressant, Anafranil is indicated for

Upsher-Smith, NASPA honor pharmacists

Upsher-Smith, NASPA honor pharmacists

MAPLE GROVE, Minn. — Upsher-Smith Laboratories Inc. and the National Alliance of State Pharmacy Associations (NASPA) have recognized the efforts 43 pharmacists from across the nation with the 2016 NASPA Excellence in Innovation Award. Upsher-Smith said Wednesday that the pharmacists were honored for their outstanding contributions to the pharmacy profession. Sponsored by Upsher-Smith, the award is

Upsher-Smith promotes Field to president

Upsher-Smith promotes Field to president

MAPLE GROVE, Minn. — Rusty Field, chief commercial officer at Upsher-Smith Laboratories Inc., has been appointed as president of the company. Upsher-Smith said Monday that in the new role, Field will be responsible for delivering revenue and profitability to meet the pharmaceutical company’s growth objectives. He reports directly to chief executive officer Mark Evenstad. “During

Upsher-Smith gains approval for Namenda generic

MAPLE GROVE, Minn. — Upsher-Smith Laboratories Inc. has received approval from the Food and Drug Administration of an Abbreviated New Drug Application (ANDA) for memantine hydrochloride tablets, a treatment for Alzheimer’s disease, in strengths of 5 mg and 10 mg. Upsher-Smith said Monday that its product is a generic version of Namenda from Forest Laboratories,